

Silva Pharmaceuticals Limited

Un-Audited Financial Statements (Third Quarter)

For the Period from 01 July, 2018 to 31 March, 2019

Silva Pharmaceuticals Limited
Statement of Financial Position
(Un-Audited)
As at 31 March, 2019

Particulars	Amount in Taka	
	31-Mar-19	30-Jun-18
ASSETS		
Non Current Assets	1,171,073,083	1,088,236,707
Property, Plant & Equipment	926,295,169	890,460,110
Capital work-in-Progress	244,777,914	197,776,597
Current Assets	1,097,520,385	913,520,356
Inventories	389,933,108	389,774,512
Trade and Other Receivables	261,351,058	249,791,383
Advances, Deposits and Prepayments	132,928,413	138,657,501
Investment in FDR	85,000,000	85,000,000
Cash and Cash Equivalents	228,307,806	50,296,960
Total Assets	2,268,593,468	2,001,757,063
SHAREHOLDERS EQUITY AND LIABILITIES:		
Equity attributable to the Shareholders	2,109,654,549	1,710,561,004
Share Capital	1,300,000,000	1,000,000,000
Retained Earnings	809,654,549	710,561,004
Non-Current Liabilities	67,030,810	91,219,792
Deferred Tax Liabilities	67,030,810	91,219,792
Current Liabilities	91,908,109	199,976,267
Trade and Other Payables	4,948,314	4,461,993
Current Portion of Long term Loan	-	99,000,000
Provision for Expenses	86,959,795	96,514,274
Total Liabilities	158,938,919	291,196,059
Total Equity & Liabilities:	2,268,593,468	2,001,757,063
Net Assets Value (NAV) per share	16.23	17.11

The annexed notes are form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: April 29, 2019

Silva Pharmaceuticals Limited
Statements of Profit or Loss and other Comprehensive Income
(Un-Audited)
For the Third Quarter ended 31 March, 2019

Particulars	Amount in Taka			
	Third Quarter ended Results		Quarterly Results	
	01/07/2018 to 31/03/2019	01/07/2017 to 31/03/2018	01/01/2019 to 31/03/2019	01/01/2018 to 31/03/2018
Turnover	557,262,668	517,397,763	186,681,154	168,528,645
Cost of goods sold	(328,120,441)	(304,732,985)	(107,182,740)	(100,351,131)
Gross Profit	229,142,227	212,664,778	79,498,414	68,177,514
Operating expenses	(100,771,776)	(93,041,993)	(34,974,274)	(32,138,208)
Operating Income	128,370,451	119,622,785	44,524,140	36,039,306
Financial expenses	(3,613,899)	(2,871,904)	-	(2,722,500)
Net Operating Profit	124,756,552	116,750,881	44,524,140	33,316,806
Interest and Other income	7,124,520	7,369,121	2,407,949	2,434,955
Net Profit before Contribution to WPPF	131,881,072	124,120,002	46,932,089	35,751,761
Provision for Contribution to Worker's Profit Participation fund (WPPF)	(6,280,051)	(5,910,476)	(2,234,861)	(1,702,465)
Net Profit before Income Tax	125,601,021	118,209,526	44,697,228	34,049,296
Income Tax Expenses:	(6,066,002)	(41,574,080)	(11,174,307)	(11,917,254)
Current Tax Expenses	(30,254,984)	(37,685,743)	(10,288,816)	(10,302,479)
Deferred Tax expenses	24,188,982	(3,888,337)	(885,491)	(1,614,775)
Net Profit after tax	119,535,019	76,635,446	33,522,921	22,132,042
Basic Earnings Per Share (EPS)	0.97	0.77	0.26	0.22
Weighted Average Number of Shares	123,430,657	100,000,000	130,000,000	100,000,000


The annexed notes are form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: April 29, 2019

Silva Pharmaceuticals Limited
Statement of Changes in Equity
(Un-Audited)

For the Third Quarter ended 31 March, 2019

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2018	1,000,000,000	710,561,004	1,710,561,004
Issue of Share Capital	300,000,000	-	300,000,000
Net profit after tax during the period	-	119,535,019	119,535,019
IPO Expenses Paid	-	(20,441,474)	(20,441,474)
Balance as at 31 March, 2019	1,300,000,000	809,654,549	2,109,654,549

For the Third Quarter ended 31 March, 2018

Particulars	<i>(Amount in Taka)</i>		
	Share Capital	Retained Earnings	Total
Balance as on 1st July, 2017	1,000,000,000	647,797,063	1,647,797,063
Net profit after tax during the period	-	76,635,446	76,635,446
Dividend	-	(30,230,000)	(30,230,000)
Balance as at 31 March, 2018	1,000,000,000	694,202,509	1,694,202,509

The annexed notes form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;
Dated: April 29, 2019

Silva Pharmaceuticals Limited

Statement of Cash Flows

(Un-Audited)

For the Third Quarter ended 31 March, 2019

Particulars	Amount in Taka	
	01/07/2018 to 31/03/2019	01/07/2017 to 31/03/2018
Cash flows from Operating Activities		
Cash received from Customers	543,815,114	521,299,685
Cash received from non-operating income	9,012,399	9,103,683
Cash Paid to Suppliers	(290,973,593)	(272,233,039)
Cash Paid to Employees	(89,662,266)	(77,387,975)
Cash Paid for Others	(19,543,745)	(39,346,674)
Income Tax Paid	(28,535,090)	(45,374,234)
Net cash inflow/(outflow) from operating activities (A)	124,112,819	96,061,446
Cash flows from Investing Activities		
Acquisition of Property, Plant and Equipment	(74,070,967)	(39,213,942)
Cash Payments for Capital Work-in-progress	(47,001,317)	(51,480,600)
Cash Payments for FDR	-	22,500,000
Cash Payments for Advance against acquisition of land	-	(30,000,000)
Net cash inflow/(outflow) from investing activities (B)	(121,072,284)	(98,194,542)
Cash flows from Financing Activities		
Long Term Loan received/(Repaid)	(99,000,000)	-
Issuance of Share Capital	300,000,000	-
Cash payment for IPO Expenses	(20,441,474)	-
Dividend Paid	-	(30,230,000)
Cash payment for Financial Expenses	(5,588,215)	(2,722,500)
Net cash inflow/(outflow) from financing activities (C)	174,970,311	(32,952,500)
Net increase/(decrease) of Cash and Cash Equivalents (A+B+C)	178,010,846	(35,085,596)
Cash and Cash Equivalents at the beginning of the period	50,296,960	83,509,106
Cash and Cash Equivalents at the end of the period	228,307,806	48,423,510
Net Operating Cash Flow Per Share	1.01	0.96

The annexed notes form an integral part of these financial statements.



Chairman



Managing Director



Director



Chief Financial Officer



Company Secretary

Place: Dhaka;

Dated: April 29, 2019